Normal levels of peripheral CD19 +CD5 + CLL-like cells: Toward a defined threshold for CLL follow-up-A GEIL-GOELAMS study

Cytometry Part B - Clinical Cytometry

Volumn 80 B, Issue 6, 2011, Pages 346-353

  Durrieu, Françoise ^a   Geneviève, Franck ^b   Arnoulet, Christine ^c   Brumpt, Caren ^d   Capiod, Jean Claude ^e   Degenne, Michel ^f   Feuillard, Jean ^g   Garand, Richard ^h   Kara Terki, Amina ⁱ   Kulhein, Emilienne ^j   Maynadié, Marc ^k   Ochoa Noguera, Maria Elena ^l   Plesa, Adriana ^m   Roussel, Mikael ⁿ   Eghbali, Houchingue ^a   Truchan Graczyk, Matgorzata ^b   De Carvalho Bittencourt, Marcelo ^o   Feugier, Pierre ^o   Béné, Marie C ^o  

^a INSTITUT BERGONIÉ   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d BEAUJON HOSPITAL   (France)

^e AMIENS UNIVERSITY HOSPITAL   (France)

^f CHU BRETONNEAU   (France)

^g DUPUYTREN UNIVERSITY HOSPITAL   (France)

^h HÔTEL DIEU   (France)

ⁱ HÔPITAL PAUL BROUSSE   (France)

^j CHU PURPAN   (France)

^k HÔPITAL DU BOCAGE   (France)

^l SAINT LOUIS HOSPITAL   (France)

^m EDOUARD HERRIOT HOSPITAL   (France)

ⁿ PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^o CHU NANCY BRABOIS   (France)

more..

Author keywords

CD19+CD5+ B cells; chronic lymphocytic leukemia; flow cytometry; minimal residual disease

Indexed keywords

CD19 ANTIGEN; CD22 ANTIGEN; CD5 ANTIGEN; CD79B ANTIGEN; CD81 ANTIGEN; LEUKOSIALIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL LEVEL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD19; ANTIGENS, CD5; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY; VIDARABINE;

EID: 80054687035     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20613     Document Type: Article

References (29)

1. Jackson SM, Wilson PC, James JA, Capra JD,. Human B cell subsets. Adv Immunol 2008; 98: 151-224.
2. Lee J, Kuchen S, Fischer R, Chang S, Lipsky PE,. Identification and characterization of a human CD5+ pre-naive B cell population. J Immunol 2009; 182: 4116-4126.
3. Perez-Andres M, Paiva B, Nieto WG, Caraux A, Schmitz A, Almeida J, Vogt RF Jr, Marti GE, Rawstron AC, Van Zelm MC, et al. Primary Health Care Group of Salamanca for the Study of MBL. Human peripheral blood B-cell compartments: A crossroad in B-cell traffic. Cytometry Part B 2010; 78B (Suppl 1): S47-S60.
4. Davis BH, Holden JT, Béné MC, Borowitz MJ, Braylan RC, Cornfield D, Gorczyca W, Lee R, Maiese R, Orfao A, et al. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical indications. Cytometry Part B 2007; 72B (Suppl 1): S5-S13. (Pubitemid 350194343)
5. Caligaris-Cappio F, Gobbi M, Bofill M, Janossy G,. Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia. J Exp Med 1982; 155: 623-628. (Pubitemid 12171305)
6. Berland R, Wortis HH,. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002; 20: 253-300. (Pubitemid 34293426)
7. Dono M, Cerruti G, Zupo S,. The CD5+ B-cell. Int J Biochem Cell Biol 2004; 36: 2105-2111. (Pubitemid 39094432)
8. Hardy R,. R. B-1 B cell development. J Immunol 2006; 177: 2749-2754.
9. Caligaris-Cappio F, Ghia P,. The normal counterpart to the chronic lymphocytic leukemia B cell. Best Pract Res Clin Haematol 2007; 20: 385-397. (Pubitemid 47250495)
10. Kazbay K, Osterland CK,. The frequency of Leu 1+B cells in autoantibody positive and negative autoimmune diseases and in neonatal cord blood. Clin Exp Rheumatol 1990; 8: 231-235. (Pubitemid 20239571)
11. Youinou P, Mackenzie L, Jouquan J, Le Goff P, Lydyard PM,. CD5 positive B cells in patients with rheumatoid arthritis: Phorbol ester mediated enhancement of detection. Ann Rheum Dis 1987; 46: 17-22. (Pubitemid 17225124)
12. Ghia P, Prato G, Scielzo C, Stella S, Geuna M, Guida G, Caligaris-Cappio F,. Monoclonal CD5+ and CD5- B-lymphocyte expansion are frequent in the peripheral blood of the elderly. Blood 2004; 103: 2337-2342. (Pubitemid 38326255)
13. Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, Evans PA, O'Connor SJ, Richards SJ, Morgan GJ, Jack AS, Hillmen P,. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002; 100: 635-639. (Pubitemid 34761129)
14. Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956-964. (Pubitemid 46672072)
15. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
16. Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, Matutes E, Milligan D,. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004; 125: 294-317. (Pubitemid 38621761)
17. Rawstron AC, Kennedy B, Moreton P, Dickinson AJ, Cullen MJ, Richards SJ, Jack AS, Hillmen P,. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004; 103: 2027-2031. (Pubitemid 38326216)
18. Esteve J, Villamor N, Colomer D, Montserrat E,. Different clinical value of MRD after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Blood 2002; 99: 1873-1874. (Pubitemid 34533068)
19. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G, Eichhorst GB, Busch R, Diem H, Engert A, et al. German CLL Study Group (GCLLSG), Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093-1101. (Pubitemid 38786968)
20. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, Tighe J, Oscier D, Fegan C, Rawstron A, et al. Eradication of MRD in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-2979. (Pubitemid 46224116)
21. Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication. Clin Cancer Res 2008; 14: 155-161. (Pubitemid 351377991)
22. Rawstron AJ, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, Russell NH, Hale G, Morgan GJ, Jack AS, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29-35.
23. Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Oña F,. CD79b expression in B cell chronic lymphocytic leukemia: Its implication for minimal residual disease detection. Leukemia 1999; 13: 1501-1505. (Pubitemid 29465610)
24. D'Arena G, Cascavilla N, Musto P, Colella Bisogno R, Pistolese G, Carotenuto M,. CD79b expression in B-cell chronic lymphocytic leukemia. Haematologica 2000; 85: 556-557. (Pubitemid 30428587)
25. McCarron KF, Hammel JP, Hsi ED,. Usefulness of CD79b expression in the diagnosis of B-cell chronic lymphoproliferative disorders. Am J Clin Pathol 2000; 113: 805-813. (Pubitemid 33051516)
26. Jung G, Eisenmann JC, Thiebault S, Henon P,. Cell surface CD43 determination improves diagnostic precision in late B-cell diseases. Br J Haematol 2003; 120: 496-499. (Pubitemid 36241510)
27. Huang J, Fan G, Zhong Y, Gatter K, Braziel R, Gross G, Bakke A,. Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry. Am J Clin Pathol 2005; 123: 826-832. (Pubitemid 40740679)
28. Béné MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, Lacombe F, Lemez P, Marinov I, Matutes E, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: A consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 2011; 25: 567-574.
29. Bottcher S, Ritgen M, Pott C, Brüggemann M, Raff T, Stilgenbauer S, Döhner H, Dreger P, Kneba M,. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004; 18: 1637-1645. (Pubitemid 39386342)